Takeda Pharmaceutical Company Limited

Thank you very much for taking time out of your very busy schedule to join Takeda's FY25 Q2 earnings announcement.

On the MC today, head of IR, my name is O'Reilly. Thank you for this opportunity.

Allow me to explain about the language setting first. Please find the language selection button at the bottom of your Zoom window. If you wish to listen in Japanese, please select Japanese. If you wish to listen in English, please select English. Or if you prefer the original voice, please keep this choice off. Before starting, I'd like to remind everyone that we'll be discussing forward-looking statements within the meaning of the Private Securities Litigation Reforms Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in our most recent Form 20F and in our other SEC filings. It is also referred to the important notice on page 2 of the presentation regarding forward-looking statements on our non-IFRS financial measures, which will also be discussed during this call. Definitions of our non-IFRS measures and reconciliations with the comparable IFRS financial measures are included in the appendix for the presentation. Now, we'd like to start with the presentation of the day. We have Christophe Weber, President and CEO, Mirano Furuta, Chief Financial Officer, Andy Phuong, President, R&D, Thirisab Iketi, President, Global Oncology Business Unit, Ike Moro, Head of Oncology Therapeutic Area Unit, will provide you with presentations, which will be followed by Q&A session.